A major proportion of CRC patients (14/19; 74%) also harbored alterations in one or more genes in P53 signaling pathway including TP53 (11/19), ATM (1/19), and ATR (1/19) (encoding DNA damage proteins); EP300 (2/19) and EP400 (2/19) (encoding a P53 coactivator), which is consistent with findings from other studies (Lee et al., 2014; Yu et al., 2014). The gene discussed is PROS1; the disease is colorectal carcinoma.